PRNewsWire · 22 Sept 2026positive
Cypherpunk Technologies announced the appointment of Amanda Fabiano to its Board of Directors. The company also reported that its newly launched 4.2 GSol/s Zcash mining fleet generated 3,023.13 ZEC in its first weeks of operation, which was added to its treasury.
Why it matters — The appointment brings mining industry expertise from firms like Nakamoto, TeraWulf, Galaxy, and Fidelity to the board, while the early ZEC production results show progress for the company's mining operations.
Seeking Alpha · 25 Aug 2026neutral
Cypherpunk Technologies holds a significant ZEC treasury and has acquired a major Zcash mining operation, boosting its asset value. Recent ZEC price surges and the Zcash ETF launch have driven CYPH's valuation, but the stock's rapid rise has consumed much of its immediate upside, and its fully diluted share count and complex capital structure mean headline market cap understates the price investors pay for exposure.
Why it matters — A CYPH watcher would care because the stock's valuation may already reflect much of the benefit from its Zcash exposure, and the complex capital structure could mean investors are paying more than the headline market cap suggests.
PRNewsWire · 18 Aug 2026positive
Cypherpunk Technologies announced the launch of Cypherpunk Mining, described as the world's largest Zcash mining fleet, via a $33.33 million equity-based transaction with Winklevoss Capital that activates 4.2 GSol/s of live, U.S.-based hashrate — approximately 18% of the Zcash network. Industry veteran Kevin Zhang joins as Head of Mining.
Why it matters — This transaction significantly expands Cypherpunk's mining operations and positions it as a major participant in the Zcash network, making it a notable development for CYPH watchers.
PRNewsWire · 12 Aug 2026neutral
Cypherpunk Technologies Inc. (Nasdaq: CYPH) reported its financial results for the second quarter ended June 30, 2026, announced via PRNewswire on Aug. 12, 2026.
Why it matters — CYPH watchers would care because the company's quarterly financial results provide key information about its recent performance.
PRNewsWire · 12 Aug 2026positive
Leap Therapeutics, the biotechnology subsidiary of Cypherpunk Technologies Inc. (CYPH), announced the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research. The peer-reviewed analyses establish baseline plasma DKK1 as a continuous quantitative biomarker predicting deepening sirexatamab benefit in second-line metastatic colorectal cancer patients, with improved response, progression-free survival, and overall survival when added to bevacizumab and chemotherapy in DKK1-high patients.
Why it matters — For CYPH watchers, this peer-reviewed publication validates the biomarker-driven clinical data behind the company's lead oncology asset, potentially informing the value of its biotechnology subsidiary.
